Acute Inflammatory Diseases in Children Clinical Trial
— SepsiXOfficial title:
Study of the Sex Differences in Inflammatory Diseases in Children
Sexual differences in innate immune response have been demonstrated and were mainly attributed to the influence of the sex steroids (1-18). However, recent clinical data revealed significant differences in inflammatory markers between boys and girls suffering from acute and chronic inflammatory diseases (19-23). Sex hormone levels in prepubertal children are particularly low and insufficient to explain the gender differences observed in inflammatory conditions from neonates to the elderly, suggesting the contribution of another mechanism, such as the influence of genes situated on the sex chromosomes and involved in the inflammatory response. The aim of this work is to evaluate the role of the X chromosome in the sex differences in inflammatory diseases in children. In order to discriminate more precisely the role of the X chromosome relatively to the sex steroids in the sex-specific inflammatory response, some innate immune functions related to X-linked genes will be evaluated in whole blood from prepubertal children of both sexes, suffering from acute inflammatory processes such as pyelonephritis caused by Escherichia coli, pneumonia with pleural effusion caused by Streptococcus pneumoniae or sepsis
| Status | Recruiting |
| Enrollment | 160 |
| Est. completion date | December 31, 2023 |
| Est. primary completion date | December 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 6 Months to 7 Years |
| Eligibility | Inclusion Criteria of Experimental group : - Male (XY) and female (XX) aged from 6 months to 7 years old. - Subject hospitalized either for: (1) Urinary tract infection caused by Escherichia Coli, with: - Temperature = to 38,5°C - Urinalysis - Leukocyte esterase + - AND/OR Nitrites + - AND/OR pyuria (= 100WBC/mm³) - AND/OR bacteriuria. - Urinalysis - Clean catch voided urine: > 10^4 Escherichia Coli colony form unit (CFU)/mm (urine collection method for children >3 years old or toilet trained children or by stimulation for children <3 years old) - Transurethral bladder catheterisation: > 10^4 Escherichia Coli colony form unit (CFU)/mm³ (urine collection method for children <3 years old). - Suprapubic aspiration: > 1 Escherichia Coli colony form unit (CFU)/mm³ (urine collection method for children <3 years old). (2) Pneumonia with pleural effusion with : - Temperature = 38,5°C - Chest radiography/ultrasound: Pleural effusion - Streptococcus pneumoniae identified on blood or pleural fluid culture or by PCR (3) Sepsis with: - Documented or suspected infection - Temperature < 36° or > 38.3°C - Heart rhythm: - 2 SD above normal for age - 6-23 months: >180/min - 24-71 months: >140/min - 72-84 months: >130/min - Respiratory Rate: - 6-23 months: >35/min - 24 - 71 months: >30/min - 72-84 months: >20/min - WBC: - 6-23 months: >17500/µL or <5000/µL - 24-71 months: >15500/µL or <6000/µL - 72-84 months: >13500/µL or <4500/µL - and/or CRP (blood) > 2SD above normal - And at least two of the following: - PaO2/FiO2 <300 - Proven need for >50% FiO2 to maintain saturation = 92% - Need for mechanical ventilation - Glasgow score < 11 - Urine output < 0,5mL/kg/h for at least 2h - Creatinine: - 6-11 months: >0,4mg/dL - 12-23 months: >0,5mg/dL - 24-59 months: >0,8mg/dL - 60-84 months: >1mg/dL - Or creatinine increase more than 0,5 mg/dL - Platelet count <100000/mL - Bilirubin >2 mg/dL - Mean arterial pressure (MAP) - 6-11 months: <55 mmHg - 12 -23 months: <60 mmHg - 24-59 months: <62 mmHg - 60-84 months: <65 mmHg - SBP less than two SD below normal for age - Prolonged capillary refill: > 5 sec Inclusion Criteria of Control group : - Male (XY) and female (XX) aged from 6 months to 7 years old. - Scheduled surgical intervention for a non-infectious pathology. Exclusion Criteria: - Use of antithrombotic drugs (acetylsalicylic acid, thienopyridines, dipyridamol, glycoprotein IIb / IIIa antagonists, vitamin K antagonists, heparins). - Congenital or acquired immunodeficiency: immunosuppressive drugs, hematopoietic stem cells transplantation, immunoglobulin therapy, extracorporeal membrane oxygenation (ECMO). - Hemodialysis. - 48h following cardiac operation of any type. - Malignant cancer. - HIV. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | HUDERF | Brussels |
| Lead Sponsor | Collaborator |
|---|---|
| Queen Fabiola Children's University Hospital | Belgium Kid's Fund |
Belgium,
Ahmed SA, Talal N. Sex hormones and the immune system--Part 2. Animal data. Baillieres Clin Rheumatol. 1990 Apr;4(1):13-31. Review. — View Citation
Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: cardiovascular and immunological aspects. Virulence. 2014 Jan 1;5(1):12-9. doi: 10.4161/viru.26982. Epub 2013 Nov 5. Review. — View Citation
Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 2013 Jun;19(7):1421-7. doi: 10.1097/MIB.0b013e318281334d. — View Citation
Bösch F, Angele MK, Chaudry IH. Gender differences in trauma, shock and sepsis. Mil Med Res [Internet]. 2018 Oct 26 [cited 2019 Mar 3];5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203206/
Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005 Jul-Aug;11(4):411-23. Epub 2005 Apr 7. Review. — View Citation
Carr MJ, Moss E, Waters A, Dean J, Jin L, Coughlan S, Connell J, Hall WW, Hassan J. Molecular epidemiological evaluation of the recent resurgence in mumps virus infections in Ireland. J Clin Microbiol. 2010 Sep;48(9):3288-94. doi: 10.1128/JCM.00434-10. Epub 2010 Jul 21. — View Citation
Casimir GJ, Heldenbergh F, Hanssens L, Mulier S, Heinrichs C, Lefevre N, Désir J, Corazza F, Duchateau J. Gender differences and inflammation: an in vitro model of blood cells stimulation in prepubescent children. J Inflamm (Lond). 2010 Jun 2;7:28. doi: 10.1186/1476-9255-7-28. — View Citation
Casimir GJ, Lefèvre N, Corazza F, Duchateau J. Sex and inflammation in respiratory diseases: a clinical viewpoint. Biol Sex Differ. 2013 Sep 1;4:16. doi: 10.1186/2042-6410-4-16. eCollection 2013. Review. — View Citation
Casimir GJ, Mulier S, Hanssens L, Knoop C, Ferster A, Hofman B, Duchateau J. Chronic inflammatory diseases in children are more severe in girls. Shock. 2010 Jul;34(1):23-6. doi: 10.1097/SHK.0b013e3181ce2c3d. — View Citation
Casimir GJ, Mulier S, Hanssens L, Zylberberg K, Duchateau J. Gender differences in inflammatory markers in children. Shock. 2010 Mar;33(3):258-62. doi: 10.1097/SHK.0b013e3181b2b36b. — View Citation
Ceribelli A, Satoh M, Chan EK. MicroRNAs and autoimmunity. Curr Opin Immunol. 2012 Dec;24(6):686-91. doi: 10.1016/j.coi.2012.07.011. Epub 2012 Aug 14. Review. — View Citation
Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy. 2008 Nov;63(11):1418-27. doi: 10.1111/j.1398-9995.2008.01880.x. Review. — View Citation
Dorhoi A, Iannaccone M, Farinacci M, Faé KC, Schreiber J, Moura-Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Müller D, Jörg S, Heinemann E, Hahnke K, Löwe D, Del Nonno F, Goletti D, Capparelli R, Kaufmann SH. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest. 2013 Nov;123(11):4836-48. — View Citation
Fogarty A, Hubbard R, Britton J. International comparison of median age at death from cystic fibrosis. Chest. 2000 Jun;117(6):1656-60. — View Citation
Johnston CM, Lovell FL, Leongamornlert DA, Stranger BE, Dermitzakis ET, Ross MT. Large-scale population study of human cell lines indicates that dosage compensation is virtually complete. PLoS Genet. 2008 Jan;4(1):e9. doi: 10.1371/journal.pgen.0040009. Epub 2007 Dec 13. — View Citation
Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. Curr Protoc Bioinformatics. 2011 Dec;Chapter 10:Unit 10.7.. doi: 10.1002/0471250953.bi1007s36. — View Citation
Lahita RG. Sex hormones and the immune system--Part 1. Human data. Baillieres Clin Rheumatol. 1990 Apr;4(1):1-12. Review. — View Citation
Lefèvre N, Corazza F, Duchateau J, Desir J, Casimir G. Sex differences in inflammatory cytokines and CD99 expression following in vitro lipopolysaccharide stimulation. Shock. 2012 Jul;38(1):37-42. doi: 10.1097/SHK.0b013e3182571e46. — View Citation
Lefèvre N, Noyon B, Biarent D, Corazza F, Duchateau J, Casimir G. Sex Differences in Inflammatory Response and Acid-Base Balance in Prepubertal Children with Severe Sepsis. Shock. 2017 Apr;47(4):422-428. doi: 10.1097/SHK.0000000000000773. — View Citation
Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002 Oct;2(10):725-34. Review. Erratum in: Nat Rev Immunol 2002 Dec;2(12):975. — View Citation
Martin GS, Mannino DM, Eaton S, Moss M. The Epidemiology of Sepsis in the United States from 1979 through 2000 [Internet]. http://dx.doi.org/10.1056/NEJMoa022139. 2009 [cited 2019 Feb 27]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa022139?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov
McClelland EE, Smith JM. Gender specific differences in the immune response to infection. Arch Immunol Ther Exp (Warsz). 2011 Jun;59(3):203-13. doi: 10.1007/s00005-011-0124-3. Epub 2011 Mar 26. Review. — View Citation
Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, Lowe L, Chen R, Shivraj L, Agadir A, Campos R, Ernst D, Gaur A. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol. 2004 Mar;110(3):252-66. Review. — View Citation
Moss M, Mannino DM. Race and gender differences in acute respiratory distress syndrome deaths in the United States: an analysis of multiple-cause mortality data (1979- 1996). Crit Care Med. 2002 Aug;30(8):1679-85. — View Citation
O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010 Feb;10(2):111-22. doi: 10.1038/nri2708. Review. — View Citation
Raghavan D, Varkey A, Bartter T. Chronic obstructive pulmonary disease: the impact of gender. Curr Opin Pulm Med. 2017 Mar;23(2):117-123. doi: 10.1097/MCP.0000000000000353. Review. — View Citation
Schoeneberg C, Kauther MD, Hussmann B, Keitel J, Schmitz D, Lendemans S. Gender-specific differences in severely injured patients between 2002 and 2011: data analysis with matched-pair analysis. Crit Care. 2013 Nov 29;17(6):R277. doi: 10.1186/cc13132. — View Citation
Schröder J, Kahlke V, Staubach KH, Zabel P, Stüber F. Gender differences in human sepsis. Arch Surg. 1998 Nov;133(11):1200-5. — View Citation
Spolarics Z. The X-files of inflammation: cellular mosaicism of X-linked polymorphic genes and the female advantage in the host response to injury and infection. Shock. 2007 Jun;27(6):597-604. Review. — View Citation
Sweezey NB, Ratjen F. The cystic fibrosis gender gap: potential roles of estrogen. Pediatr Pulmonol. 2014 Apr;49(4):309-17. doi: 10.1002/ppul.22967. Epub 2013 Dec 11. Review. — View Citation
The effect of sex on asthma control from the National Asthma Survey - Journal of Allergy and Clinical Immunology [Internet]. [cited 2019 Feb 27]. Available from: https://www.jacionline.org/article/S0091-6749(08)02373-7/fulltext
Venn A, Lewis S, Cooper M, Hill J, Britton J. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. BMJ. 1998 Jun 27;316(7149):1945-6. — View Citation
Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. J Allergy Clin Immunol. 2010 Sep;126(3):498-504.e1-6. doi: 10.1016/j.jaci.2010.06.018. — View Citation
Wichmann et al. - 2000 - Incidence and mortality of severe sepsis in surgic.pdf [Internet]. [cited 2019 Feb 27]. Available from: https://link.springer.com/content/pdf/10.1007/s001340050041.pdf
Wichmann MW, Inthorn D, Andress HJ, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med. 2000 Feb;26(2):167-72. — View Citation
* Note: There are 35 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Whole blood production of cytokine IL-6 | The production of IL6 is measured by multiplex techniques. | within 24 hours of hospital admission (Day 0) | |
| Secondary | Whole blood production of cytokine IL-1ß | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Whole blood production of cytokine IL-8 | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Whole blood production of cytokine IL-10 | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Whole blood production of cytokine TNF-a | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Whole blood production of cytokine interferon-a | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Intracellular quantity of the phosphorylated forms of NF-?B p65 in leukocyte population. | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Intracellular quantity of the phosphorylated forms of ERK1/2 in leukocyte population. | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Intracellular quantity of the phosphorylated forms of p38 MAPK in leukocyte population. | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Expression of the cell diapedesis receptor CD99 on PMNs | Measurements of cell diapedesis receptor CD99 on leukocytes will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of the cell diapedesis receptor CD99 on monocytes | Measurements of cell diapedesis receptor CD99 on leukocytes will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of the cell diapedesis receptor CD99 on lymphocytes | Measurements of cell diapedesis receptor CD99 on leukocytes will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR2 on PMNs | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR2 on monocytes | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR2 on lymphocytes | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR4 on PMNs | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR4 on monocytes | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of TLR4 on lymphocytes | Measurements of intracellular phosphorylated forms of TLR pathway proteins as well as the expression of TLR2 and TLR4 will be performed by flow cytometry | within 24 hours of hospital admission (Day 0) | |
| Secondary | BTK gene expression | Measurements will be performed using the Quantitect Reverse Transcription Kit (Qiagen, Manchester, UK) for quantitative PCR (qPCR) on leucocytes. | within 24 hours of hospital admission (Day 0) | |
| Secondary | IRAK1 gene expression | Measurements will be performed using the Quantitect Reverse Transcription Kit (Qiagen, Manchester, UK) for quantitative PCR (qPCR) on leucocytes. | within 24 hours of hospital admission (Day 0) | |
| Secondary | NEMO gene expression | Measurements will be performed using the Quantitect Reverse Transcription Kit (Qiagen, Manchester, UK) for quantitative PCR (qPCR) on leucocytes. | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of X-linked miRNAs in leucocytes | Expression of X-linked miRNAs is measured by sequencing and qRT-PCR on leucocytes and/or plasma samples. | within 24 hours of hospital admission (Day 0) | |
| Secondary | Expression of X-linked miRNAs in plasma | Expression of X-linked miRNAs is measured by sequencing and qRT-PCR on leucocytes and/or plasma samples. | within 24 hours of hospital admission (Day 0) | |
| Secondary | Leukocyte population | White blood cell count including neutrophils, monocytes, monocytes subtypes and lymphocytes. | within 24 hours of hospital admission (Day 0) | |
| Secondary | Leukocyte population | White blood cell count including neutrophils, monocytes, monocytes subtypes and lymphocytes. Only applicable for the sepsis sub-group | Day 1 | |
| Secondary | Leukocyte population | White blood cell count including neutrophils, monocytes, monocytes subtypes and lymphocytes. Only applicable for the sepsis sub-group | Day 2 | |
| Secondary | Leukocyte population | White blood cell count including neutrophils, monocytes, monocytes subtypes and lymphocytes. Only applicable for the sepsis sub-group | Day 3 | |
| Secondary | CRP | within 24 hours of hospital admission (Day 0) | ||
| Secondary | CRP | Only applicable for the sepsis sub-group | Day 1 | |
| Secondary | CRP | Only applicable for the sepsis sub-group | Day 2 | |
| Secondary | CRP | Only applicable for the sepsis sub-group | Day 3 | |
| Secondary | Total 17ß-estradiol | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Testosterone | within 24 hours of hospital admission (Day 0) | ||
| Secondary | IGF1 | within 24 hours of hospital admission (Day 0) | ||
| Secondary | Microbiome analysis | During subject hospitalisation | ||
| Secondary | pSOFA score | Only applicable for the sepsis sub-group. The pSOFA will be evaluated every 24 hours in order to compare laboratory and clinical data. The score will be based on the PaO2: FiO2 or SpO2: FiO2 ratio, the platelet count, the bilirubin level, the Mean Arterial Pressure (MAP), the Glasgow score and the creatinine level. | within 24 hours of hospital admission (Day 0) | |
| Secondary | pSOFA score | Only applicable for the sepsis sub-group. The pSOFA will be evaluated every 24 hours in order to compare laboratory and clinical data. The score will be based on the PaO2: FiO2 or SpO2: FiO2 ratio, the platelet count, the bilirubin level, the Mean Arterial Pressure (MAP), the Glasgow score and the creatinine level. | Day 1 | |
| Secondary | pSOFA score | Only applicable for the sepsis sub-group. The pSOFA will be evaluated every 24 hours in order to compare laboratory and clinical data. The score will be based on the PaO2: FiO2 or SpO2: FiO2 ratio, the platelet count, the bilirubin level, the Mean Arterial Pressure (MAP), the Glasgow score and the creatinine level. | Day 2 | |
| Secondary | pSOFA score | Only applicable for the sepsis sub-group. The pSOFA will be evaluated every 24 hours in order to compare laboratory and clinical data. The score will be based on the PaO2: FiO2 or SpO2: FiO2 ratio, the platelet count, the bilirubin level, the Mean Arterial Pressure (MAP), the Glasgow score and the creatinine level. | Day 3 |